Literature DB >> 34155346

Whole-transcriptome and proteome analyses identify key differentially expressed mRNAs, miRNAs, lncRNAs and circRNAs associated with HCC.

Fang Xu1, Liya Jiang1,2, Qianwei Zhao1, Zhibiao Zhang2, Yixian Liu1, Shuangshuang Yang1, Mengdan Yu3, Huiping Chen1, Jianying Zhang4,5,6, Jintao Zhang7,8,9.   

Abstract

Hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer and one of the leading causes of cancer-related death worldwide. To gain more insights into the transcriptomic landscape and molecular mechanism of HCC, we performed TMT-labelled tandem mass spectrometry (n = 4) and whole-transcriptome sequencing (n = 3) based on HCC tumour (T) and adjacent normal (N) tissues from seven HCC patients. To comprehensively evaluate the gene-regulatory circuits in HCC, differential expression and enrichment analyses were performed on the differentially expressed proteins (DEPs), genes (DEGs), miRNAs (555), lncRNAs (29) and circRNAs (895). A total of 977 proteins and 243 genes were found to be differentially expressed in HCC tumours compared with adjacent normal tissues. HCC data from The Cancer Genome Atlas were used to validate the results. Combined with the results above, 56 DEP-DEGs with common changes in relative quantity were identified. Functional pathway analysis showed that the DEP-DEGs were mainly enriched in the spliceosome and various metabolic processes. Bioinformatics analysis showed that hsa-miR-1266-5p, hsa-miR-128-1-5p, hsa-miR-139-5p, hsa-miR-34b-3p and hsa-miR-570-3p were involved in the regulation of the hub genes mentioned above. The crucial coexpression (lncRNA-mRNA, circRNA-mRNA) and competing endogenous RNA interaction axes showed the possible functions of the lncRNAs and circRNAs. We explored potential cancer biomarkers by combining proteomic and transcriptomic studies. Our study provides a valuable resource for understanding regulatory mechanisms at the RNA level and may ultimately further assist in the development of diagnostic and/or therapeutic targets for HCC.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34155346     DOI: 10.1038/s41388-021-01908-0

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  2 in total

1.  Long non‑coding RNAs in HBV‑related hepatocellular carcinoma (Review).

Authors:  Hao Zhang; Xuebing Chen; Jian Zhang; Xianwei Wang; Huijuan Chen; Lin Liu; Shanling Liu
Journal:  Int J Oncol       Date:  2019-11-12       Impact factor: 5.650

2.  A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.

Authors:  Xu Ye; Cunyan Li; Xuyu Zu; Minglin Lin; Qiang Liu; Jianghua Liu; Guoguo Xu; Zhiyong Chen; Yongliang Xu; Long Liu; Diteng Luo; Zhe Cao; Guiyuan Shi; Zirui Feng; Hongyu Deng; Qianjin Liao; Chuan Cai; Duan-Fang Liao; Jing Wang; Junfei Jin; Deliang Cao
Journal:  Hepatology       Date:  2019-04-06       Impact factor: 17.425

  2 in total
  4 in total

1.  Molecular Insights and Prognosis Associated With RBM8A in Glioblastoma.

Authors:  Lei Wei; Chun Zou; Liechun Chen; Yan Lin; Lucong Liang; Beiquan Hu; Yingwei Mao; Donghua Zou
Journal:  Front Mol Biosci       Date:  2022-04-29

2.  MiR-107 inhibits the malignant biological behavior of esophageal squamous cell carcinoma by targeting TPM3.

Authors:  Peipei Zhang; Weiguang Zhang; Junfei Jiang; Zhimin Shen; Sui Chen; Shaobin Yu; Mingqiang Kang
Journal:  J Gastrointest Oncol       Date:  2022-08

3.  Genome-Wide Identification and Characterization of Circular RNAs during Skeletal Muscle Development in Meat Rabbits.

Authors:  Kun Du; Xiaoyu Zhao; Yanhong Li; Zhoulin Wu; Wenqiang Sun; Jie Wang; Xianbo Jia; Shiyi Chen; Songjia Lai
Journal:  Animals (Basel)       Date:  2022-08-27       Impact factor: 3.231

4.  Identification of key snoRNAs serves as biomarkers for hepatocellular carcinoma by bioinformatics methods.

Authors:  Qingqing Xie; Di Zhang; Huifeng Ye; Zhitong Wu; Yifan Sun; Haoming Shen
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.